Bicara Therapeutics, Inc. (BCAX)
22.02
-0.62
(-2.74%)
USD |
NASDAQ |
Sep 21, 16:00
22.02
0.00 (0.00%)
After-Hours: 20:00
Bicara Therapeutics EPS Diluted (Quarterly) : -0.8161 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.8161 |
| March 31, 2026 | -0.9258 |
| December 31, 2025 | -0.678 |
| September 30, 2025 | -0.6658 |
| June 30, 2025 | -0.5022 |
| March 31, 2025 | -0.6766 |
| Date | Value |
|---|---|
| December 31, 2024 | -0.385 |
| September 30, 2024 | -0.3213 |
| June 30, 2024 | -0.3133 |
| March 31, 2024 | -0.2299 |
| December 31, 2023 | -0.2286 |
| September 30, 2023 | -0.4199 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -55.44M |
| Total Expenses (Quarterly) | 55.44M |
| Enterprise Value | 996.58M |
| Earnings Yield | -14.01% |
| Normalized Earnings Yield | -14.01 |